Hitting HIV hard with HAART therapy
The human immunodeficiency virus (HIV), discovered in 1984 , is a retrovirus that causes progressive failure of the immune system, resulting in the development of opportunistic infections and cancers (acquired immunodeficiency syndrome, or AIDS). Development of therapies is imperative to stop viral replication and progression of the disease.
Soon after HIV was found to be the cause of AIDS, Samuel Broder, M.D., Hiroaki Mitsuya, M.D., Ph.D., and Robert Yarchoan, M.D., demonstrated that certain nucleoside reverse transcriptase inhibitors had activity against HIV in the test tube, a discovery the team rapidly moved to test in clinical trials.
This research yielded the first drugs approved by the U.S. FDA for the treatment of HIV infection: zidovudine (AZT) in 1985, didanosine (ddI) in 1991, and zalcitabine (ddC) in 1992. These drugs became the foundation for highly active antiretroviral therapies (HAART), saving countless lives.
Yarchoan R, Mitsuya H, Thomas RV, Pluda JM, Hartman NR, Perno CF, Marczyk KS, Allain JP, Johns DG, Broder S. (1989). In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science. 245(4916), 412-5.